Boston, MA - A new study confirms that the presence of left ventricular outflow tract obstruction, occurring in about a quarter of patients with hypertrophic cardiomyopathy (HCM), is a "strong, ...

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of ...

PHILADELPHIA, March 29, 2026 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) reported today that adolescents with hypertrophic cardiomyopathy (HCM) who took mavacamten ...

Background A 42-year-old woman with a 20-year history of obstructive hypertrophic cardiomyopathy was referred for alcohol septal ablation following a worsening of symptoms, which had persisted despite ...

Mavacamten improves heart function and symptoms in patients with obstructive hypertrophic cardiomyopathy, according to results of the EXPLORER-HCM trial presented in a Hot Line session today at ESC ...

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, ...

Athletes with mild hypertrophic cardiomyopathy (HCM) at low risk of sudden cardiac death (SCD) can safely continue to exercise at competitive levels, a retrospective study suggests. During a mean ...

Credit: Getty Images HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C. Hypertrophic cardiomyopathy (HCM) ...

After presenting the results of the EXPLORER-HCM study (NCT03470545) at the European Society of Cardiology Congress 2020 – The Digital Experience, Iacopo Olivotto, MD, addressed questions from the ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten did not improve outcomes vs. placebo at 48 weeks in patients with nonobstructive hypertrophic ...